A third of patients with urinary tract infections fail antibiotic treatment even when lab tests show the bacteria should be susceptible—because the bacteria have stopped growing and entered a dormant state that standard drugs cannot touch. This research tackles a blind spot in the antibiotic crisis. Most drug development focuses on killing actively growing bacteria, but in real infections—especially in people with weakened immune systems—bacteria often face stresses that force them into a low-activity, drug-tolerant state. These dormant cells survive treatment and can later acquire true genetic resistance. The project screens for compounds that kill *E. coli* and *Pseudomonas aeruginosa* while they are under infection-relevant stress and tolerating standard antibiotics, then uses fundamental biology to understand why those compounds work. If successful, the approach could produce drug candidates that clear chronic infections rather than just suppressing them, reducing the reservoir of bacteria that evolve into resistant strains. The work is early-stage and primarily curiosity-driven, but by mimicking infection conditions in the lab rather than ideal growth conditions, it addresses a known reason why promising antibiotics fail in the clinic.
View original technical description
Increasing attention has been focused on the growing problem of antibiotic resistance. It is estimated that there are approximately 1.3 million deaths per year due to bacterial infections that cannot be effectively treated with the antibiotics we have relied on in the past, because the bacteria have become resistant to them and can continue to grow in their presence. This problem is expected to become worse. However, currently, many more people die from infections caused by bacteria that are considered sensitive to antibiotics than from infections due to antibiotic-resistant bacteria. These infections usually affect people whose immune system is compromised in some way. The bacteria causing the infection are sensitive to the antibiotics being used when they are tested in the laboratory under ideal conditions, but the antibiotics still fail to clear the infection, leading to chronic or recurrent disease. The bacteria manage to tolerate exposure to the antibiotic, even though they cannot grow in its presence. It appears that stresses the bacteria experience in infections can cause them to stop growing, which increases their ability to tolerate antibiotics, because most antibiotics target processes that are associated with growth. The problems of antibiotic tolerance and antibiotic resistance are related: tolerance can serve as a stepping stone to resistance. Bacteria that survive exposure to an antibiotic by adopting a low-activity, antibiotic-tolerant state have opportunities to acquire mutations that confer resistance to that antibiotic and allow them to continue growing if they are exposed to the same antibiotic again. It is urgent that we develop new antibiotics, but progress in this area has faltered. The research described here will specifically focus on developing new therapies to target antibiotic-tolerant bacteria. We have worked to improve our understanding of how bacteria tolerate antibiotics, by studying the processes they rely on when they are not actively growing due to a stress that they are likely to encounter in an infection. We have identified distinct pathways that are more important during growth arrest. We are now working to find compounds that can kill bacteria while they are exposed to an infection-relevant stress, and while they are successfully tolerating a standard antibiotic. We will apply this strategy to finding treatments for antibiotic-tolerant Escherichia coli under conditions they might encounter in a urinary tract infection. Meanwhile, we will also develop strategies to determine exactly how compounds that are successful in our screen are able to kill the bacteria. We will first develop these strategies for compounds that kill the bacterium Pseudomonas aeruginosa under conditions that mimic lung infections, and we will use the basic research we have done on the pathways important for growth arrest in this organism to interpret the results. We will then adapt the strategy to the new compounds we find that work against E. coli. For the most successful new compounds, we will seek further funding to develop them into drug candidates. We hope that our model of (1) screening compounds against bacteria that are in a state that closely mimics the infection; then (2) seeking to deeply understand the biological reason why the compounds work, can help stimulate progress in finding new types of antibiotics that are more successful in clearing chronic infections.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know